

*Copy*

---

The information in this facsimile is confidential and is intended for the sole use of the addressee designated below. If this facsimile has been misdirected, kindly return it by postal service to Gilead Sciences, Inc. If you do not receive all pages clearly, please telephone (650) 573-4709 or 572-6535.



GILEAD SCIENCES, INC.  
333 Lakeside Drive  
Foster City, California 94404  
Telephone: 650/572-6535 or 650/574-3000  
Telefacsimile: 650/573-4899 (Patents) or 650/578-9264

Date: April 10, 1998 Telefax: (703) 308-7921

To: Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Re: In re application of: Arimilli et al  
Serial No.: 08/900,746  
Filed: July 25, 1997

**RECEIVED**

MAY 20 1998

Attorney Docket No. 221.P1  
Group No. 1613  
Examiner: M. Ambrose

From: Daryl D. Muenchau, Reg. 36,616

*Daryl D. Muenchau*

Total Number of Pages Including Cover Sheet: 85\*

**\*Due to size, facsimile is being sent in 3 separate transmissions:**

- 1) Fax transmittal through Jones et al.
- 2) Krise et al, through John A. Landgrebe
- 3) Starrett et al, through Tsai et al.

**Certification of Facsimile Transmission**

I hereby certify that this paper along with the following documents are being facsimile transmitted to the Patent and Trademark Office and that the original documents are being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.



Attorney Docket No. 221.P1  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arimilli et al.

Serial No.: 08/900,746

Group No.: 1205

Filed: July 25, 1997

Examiner: unassigned

For: NUCLEOTIDE ANALOGS

COPY

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN  
THREE MONTHS OF FILING OR BEFORE MAILING OF  
FIRST OFFICE ACTION (37 CFR 1.97 (b))

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(check and complete appropriate item below):

37 CFR 1.8 (a)

with sufficient postage as  
first class mail

or

37 CFR 1.10

as "Express Mail Post  
Office to Addressee" Mailing  
Label  
No. \_\_\_\_\_

Robin Torres

(Type or print name of person mailing paper)

Date: March 4, 1998

Robin Torres  
(Signature of person mailing paper)

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 36,616

Daryl D Muenchau  
SIGNATURE OF AGENT

Tel. No.: (650) 573-4712

Daryl D. Muenchau  
Type or print name of agent

Gilead Sciences, Inc.  
333 Lakeside Drive  
P.O. Address

Foster City, CA 94404



16P1

Attorney Docket No. 221.P1  
**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arimilli et al.

Serial No.: 08/900,746

Group No.: 1205

Filed: July 25, 1997

Examiner: unassigned

For: NUCLEOTIDE ANALOGS

**COPY**

Assistant Commissioner for Patents

Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT (modified)**

**List of Sections Forming Part of This Information Disclosure Statement.**

The following sections are being submitted for this Information Disclosure Statement:

1.  Preliminary Statements
2.  FORM PTO - 1449 (Modified)
3.  Copies of Listed Information Items Accompanying This Statement

**Section 1. Preliminary statements**

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date:

March 4, 1998

Robin Torres  
(Signature of person mailing paper)

**Section 3. Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 36,616

Daryl D. Muenchau  
SIGNATURE OF AGENT

Tel. No.: (650) 573-4712

Daryl D. Muenchau  
Type or print name of agent

Gilead Sciences, Inc.  
333 Lakeside Drive  
P.O. Address

Foster City, CA 94404